Supplementary Appendix This Appendix Formed Part of the Original Submission and Has Been Peer Reviewed
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 2020; 395: 1496–505. APPENDIX Secukinumab versus Adalimumab Comparison for the Treatment of Active Psoriatic Arthritis (EXCEED): A Randomised, Double-blind, Active-controlled Phase 3b Trial Iain B McInnes1*, Frank Behrens2, Philip J Mease3, Arthur Kavanaugh4, Christopher Ritchlin5, Peter Nash6, Jordi Gratacós Masmitja7, Philippe Goupille8, Tatiana Korotaeva9, Alice B Gottlieb10, Ruvie Martin11, Kevin Ding12, Pascale Pellet13, Shephard Mpofu14, and Luminita Pricop15 on behalf of EXCEED Study 1University of Glasgow, Glasgow, United Kingdom 2Rheumatology University Hospital and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP and Fraunhofer Cluster of Excellence for Immune- Mediated Diseases CIMD, Goethe University, Frankfurt, Germany 3Swedish Medical Centre/Providence St. Joseph Health and University of Washington, Seattle, United States 4Rheumatology, Allergy, Immunology Division, University of California, San Diego, School of Medicine, La Jolla, United States, La Jolla, United States 5Allergy/Immunology and Rheumatology Division, University of Rochester, Rochester, United States 6Department of Medicine,
[Show full text]